Multiple Sclerosis
Naltrexone for HIV/AIDS, Cancer, and Autoimmune Diseases such as Multiple Sclerosis?
Apr 19, 2005 - 11:09:38 AM

The drug naltrexone, which in a 50 mg dose was approved by the FDA many years ago for drug abuse and for alcoholism, in less than one-tenth that dosage boosts the immune system and thus helps fight any disease that is characterized by inadequate immune function.

Investigators mounting successful clinical trials, along with physicians and patients utilizing low dose naltrexone (LDN), will make panel presentations on June 11th at a conference to be held at the New York Academy of Sciences. The keynote speaker will be Bernard Bihari, MD, a Manhattan physician and the discoverer of the clinical effects of LDN.

This discovery establishes a new paradigm in medical therapy: LDN not only tends to normalize the immune system by elevating the body’s endorphin levels but also accomplishes its results with virtually no side effects or toxicity.

Two pilot studies have recently been completed, one for Crohn’s disease and one for multiple sclerosis (MS), and the principal investigators, respectively from Hershey Medical Center at Penn State and from Dr. Evers Clinic, a hospital for neurological disease in Germany, will be present.

The promise of LDN is significant because:

(a) it can halt diseases (e.g., MS and other autoimmune diseases, HIV, and many cancers) where there are no effective treatment options;

(b) it provides successful treatment while being virtually free of side effects or toxicity; and

(c) were it produced in a developing country, this generic drug would offer an extremely inexpensive ($10 per year) HIV treatment, one that does not require close supervision by health professionals—the patient need only take one small capsule each night at bedtime.

All rights reserved by RxPG Medical Solutions Private Limited ( )